PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Physiological effects of roflumilast at rest and during exercise in COPD Source: Eur Respir J 2012; 39: 1104-1112 Year: 2012
LATE-BREAKING ABSTRACT: Anti-inflammatory effect of RP6557, a dual PI3K d/? inhibitor, in glucocorticoid insensitive human neutrophils from chronic obstructive pulmonary disease patients Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015
The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015
Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
Roflumilast N-oxide combined with PI3Kδ inhibitor improves the phenotype of early-onset COPD Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Dynamics of sputum antimicrobial peptide levels in chronic obstructive pulmonary disease (COPD) Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015
Long term treatment with n-acetylcysteine reduces exacerbations in moderate chronic obstructive pulmonary disease Source: International Congress 2016 – Pharmacological management of COPD Year: 2016
Beyond corticosteroids: future prospects in the management of inflammation in COPD Source: Eur Respir Rev 2011; 20: 175-182 Year: 2011
Pharmacological actions of statins: potential utility in COPD Source: Eur Respir Rev 2009; 18: 222-232 Year: 2009
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Emerging anti-inflammatory strategies for COPD}, Source: Eur Respir J 2012; 40: 724-741 Year: 2012
Survivin in patients with chronic obstructive pulmonary disease Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015
Mucin 1 downregulation associates with corticoid resistance in chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Modulation of airway inflammation to prevent exacerbations of COPD Source: Eur Respir Rev 2005; 14: 78-82 Year: 2005
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Rosuvastatin effects on systemic inflammation, oxidative stress and antioxidants in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – COPD diagnosis and management Year: 2016
Reducing cholinergic constriction: the major reversible mechanism in COPD Source: Eur Respir Rev 2006; 15: 32-36 Year: 2006
Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011